Localization of β-Secretase Memapsin 2 in the Brain of Alzheimer's Patients and Normal Aged Controls

doi:10.1006/exnr.2002.7875

Experimental Neurology

Volume 175, Issue 1, May 2002, Pages 10-22

https://doi.org/10.1006/exnr.2002.7875 Get rights and content

Abstract

Chronic accumulation of β-amyloid in the brain has been shown to result in complex molecular and cellular changes that accompany neurodegeneration in Alzheimer's disease (AD). In this study, we examined the expression of a newly identified β-secretase, memapsin 2 (M2) or β-site APP cleaving enzyme in deparaffinized sections from 10 AD patients and 10 aged matched controls and in frozen samples of parietal cortex from 11 AD and 8 controls. M2 is mainly expressed in neurons, with high levels in CA4 to CA2 regions and transentorhinal cortex and low or intermediate levels in CA1, subiculum, and granule cells of the dentate gyrus. The majority of AD brains showed an increase of M2 expression in the CA1, but a decrease in the transentorhinal cortex. A subset of controls and AD patients had high M2 expression in parietal neocortex. Double-staining revealed that senile plaques are not directly associated with the soma of M2-expressing neurons. Neurofibrillary tangles were associated with lower M2 expression in AD. These data indicate that β-secretase M2 may not be straightforwardly involved in amyloid plaque formation in AD brain.

References (53)

B.D. Bennett et al.
Expression analysis of BACE2 in brain and peripheral tissues
J. Biol. Chem.
(2000)
B.D. Bennett et al.
A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's β-secretase
J. Biol. Chem.
(2000)
M. Bigl et al.
Expression of β-secretase mRNA in transgenic Tg2576 mouse brain with Alzheimer plaque pathology
Neurosci. Lett.
(2000)
M. Citron et al.
Generation of amyloid β protein from its precursor is sequence specific
Neuron
(1995)
J.W. Creemers et al.
Processing of β-secretase by furin and other members of the proprotein convertase family
J. Biol. Chem.
(2001)
G.K. Gouras et al.
Intraneuronal Aβ42 accumulation in human brain
Am. J. Pathol.
(2000)
J.T. Huse et al.
Maturation and endosomal targeting of β-site amyloid precursor protein-cleaving enzyme: The Alzheimer's disease β-secretase
J. Biol. Chem.
(2000)
I. Hussain et al.
Identification of a novel aspartic protease (Asp 2) as β-secretase
Mol. Cell. Neurosci.
(1999)
I. Hussain et al.
ASP1 (BACE2) cleaves the amyloid precursor protein at the β- secretase site
Mol. Cell. Neurosci.
(2000)
M.C. Irizarry et al.
β-site APP cleaving enzyme mRNA expression in APP transgenic mice: Anatomical overlap with transgene expression and static levels with aging
Am. J. Pathol.
(2001)

M. Kelliher et al.

Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and β-amyloid pathologies

Neuroscience

(1999)

Y.M. Kuo et al.

Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains

J. Biol. Chem.

(2001)

J. Li et al.

Alzheimer presenilins in the nuclear membrane, interphase kinetochores, and centrosomes suggest a role in chromosome segregation

Cell

(1997)

L.F. Lue et al.

Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease

Am. J. Pathol.

(1999)

R.P. Mason et al.

Distribution and fluidizing action of soluble and aggregated amyloid β-peptide in rat synaptic plasma membranes

J. Biol. Chem.

(1999)

J. Nunan et al.

Regulation of APP cleavage by α-, β- and γ-secretases

FEBS Lett.

(2000)

J.N. Octave et al.

The role of presenilin-1 in the γ-secretase cleavage of the amyloid precursor protein of Alzheimer's disease

J. Biol. Chem.

(2000)

M.R. Palmert et al.

Soluble derivatives of the β amyloid protein precursor of Alzheimer's disease are labeled by antisera to the β amyloid protein

Biochem. Biophys. Res. Commun.

(1989)

J.W. Putney

Presenilins, Alzheimer's disease, and capacitative calcium entry

Neuron

(2000)

A. Sun et al.

A novel fluorescent method for direct visualization of neurofibrillary pathology in Alzheimer's disease

J. Neurosci. Methods

(2001)

D.A. Turner et al.

Morphological features of the entorhinal–hippocampal connection

Prog. Neurobiol.

(1998)

J. Wang et al.

The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging

Exp. Neurol.

(1999)

C.L. Weaver et al.

Conformational change as one of the earliest alterations of tau in Alzheimer's disease

Neurobiol. Aging

(2000)

C. Wild-Bode et al.

Intracellular generation and accumulation of amyloid β-peptide terminating at amino acid 42

J. Biol. Chem.

(1997)

M.Q. Xia et al.

Lack of specific association of presenilin 1 protein with plaques and tangles in Alzheimer's disease

J. Neurol. Sci.

(1998)

W. Xia

Role of presenilin in γ-secretase cleavage of amyloid precursor protein

Exp. Gerontol.

(2000)

Cited by (40)

BACE1-dependent metabolism of neuregulin 1: Bridging the gap in explaining the occurrence of schizophrenia-like symptoms in Alzheimer's disease with psychosis?
2023, Ageing Research Reviews
Alzheimer’s disease is a neurodegenerative disease mainly characterized by cortico-neuronal atrophy, impaired memory and other cognitive declines. On the other hand, schizophrenia is a neuro-developmental disorder with an overtly active central nervous system pruning system resulting into abrupt connections with common symptoms including disorganised thoughts, hallucination and delusion. Nevertheless, the fronto-temporal anomaly presents itself as a common denominator for the two pathologies. There is even a strong presumption of increased risk of developing co-morbid dementia for schizophrenic individuals and psychosis for Alzheimer’s disease patients, overall leading to a further deteriorated quality of life. However, convincing proofs of how these two disorders, although very distant from each other when considering their aetiology, develop coexisting symptoms is yet to be resolved. At the molecular level, the two primarily neuronal proteins β-amyloid precursor protein and neuregulin 1 have been considered in this relevant context, although the conclusions are for the moment only hypotheses. In order to propose a model for explaining the psychotic schizophrenia-like symptoms that sometimes accompany AD-associated dementia, this review projects out on the similar sensitivity shared by these two proteins regarding their metabolism by the β-site APP cleaving enzyme 1.
Neuronal expression of ILEI/FAM3C and its reduction in Alzheimer's disease
2016, Neuroscience
Citation Excerpt :
Moreover, APP and components of the γ-secretase complex exhibited co-localization with ILEI. The putative major site of Aβ generation in the brain is synaptic terminals, although immunostaining for APP, BACE1 (β-secretase), and γ-secretase complex components did not reveal a synaptic pattern (Lee et al., 1996; Lah et al., 1997; Sun et al., 2002). Subcellular fractionation using mouse brain showed an overlapping distribution of synaptophysin and ILEI (Fig. 3B).
Decrease in brain amyloid-β (Aβ) accumulation is a leading strategy for treating Alzheimer’s disease (AD). However, the intrinsic mechanism of the regulation of brain Aβ production is largely unknown. Previously, we reported that ILEI (also referred to as FAM3C) binds to the γ-secretase complex and suppresses Aβ production without inhibiting γ-secretase activity. In this study, we examined ILEI expression in mouse brain using immunohistochemistry and subcellular fractionation. Brain ILEI showed widespread expression in neurons and ependymal cells but not in glial and vascular endothelial cells. Neuronal ILEI resided in perinuclear vesicular structures, which were positive for a marker protein of the trans-Golgi network. Although ILEI immunostaining was negative at synaptic terminals, synaptosome fractionation analysis suggested that ILEI was enriched in presynaptic terminals, particularly in the active zone-docked synaptic vesicles. ILEI expression levels in brain peaked during the postnatal period and declined with age. In comparison with age-matched control brains, the number of ILEI-immunoreactive neurons decreased in AD brains, although the subcellular localization was unaltered. Our results suggest that a decline of ILEI expression may cause accumulation of Aβ in the brain and the eventual development of AD.
Decrease in catalytic capacity of γ-secretase can facilitate pathogenesis in sporadic and Familial Alzheimer's disease
2015, Molecular and Cellular Neuroscience
Citation Excerpt :
Therefore, such measurements can be directly related to the pathogenic changes in Aβ products and Aβ 42/40 ratio according to differences in the Michaelis–Menten constant for each product (Kakuda et al., 2006; Svedruzic et al., 2013; Yin et al., 2007). The results in Figs. 1–3 are consistent with the previous studies on humans, experimental animals, cells, and enzymes which showed that pathogenic events correlate with increase in saturation of γ-secretase with its substrate or decrease in its maximal activity (Fukumoto et al., 2004; Jonsson et al., 2012; Holsinger et al., 2004; Li et al., 2004; Sun et al., 2002; Yang et al., 2003; Guyant-Marechal et al., 2007; Rovelet-Lecrux et al., 2006, 2007; Citron et al., 1992; Cai et al., 1993; German and Eisch, 2004; Marlow et al., 2003; Refolo et al., 1999; Svedruzic et al., 2012, 2013). For example, we find earlier “age-of-onset” and “age-of-death” with the less active (Fig. 1), more saturated FAD mutants (Fig. 2), that have lower capacity to process their β-CTF-APP substrate (Fig. 5).
Alzheimer's disease can be a result of an age-induced disparity between increase in cellular metabolism of Aβ peptides and decrease in maximal activity of a membrane-embedded protease γ-secretase.
We compared activity of WT γ-secretase with the activity of 6 FAD mutants in its presenilin-1 component and 5 FAD mutants in Aβ-part of its APP substrate (Familial Alzheimer's disease). All 11 FAD mutations show linear correlation between the decrease in maximal activity and the clinically observed age-of-onset and age-of-death. Biphasic-inhibitors showed that a higher ratio between physiological Aβ-production and the maximal activity of γ-secretase can be observed in cells that can facilitate pathogenic changes in Aβ-products. For example, Aβ production in cells with WT γ-secretase is at 11% of its maximal activity, with delta-exon-9 mutant at 26%, while with M139V mutant is at 28% of the maximal activity. In the same conditions, G384A mutant is fully saturated and at its maximal activity. Similarly, Aβ production in cells with γ-secretase complex carrying Aph1A_L component is 12% of its maximal activity, while in cells with Aph1B complex is 26% of its maximal activity. Similar to the cell-based studies, clinical studies of biphasic dose–response in plasma samples of 54 healthy individuals showed variable ratios between physiological Aβ production and the maximal activity of γ-secretase.
The increase in the ratio between physiological Aβ production and maximal activity of γ-secretase can be an early sign of pathogenic processes in enzyme-based, cell-based, and clinical studies of sporadic and Familiar Alzheimer's disease.
Shared cognitive and behavioral impairments in epilepsy and Alzheimer's disease and potential underlying mechanisms
2013, Epilepsy and Behavior
Citation Excerpt :
Indeed, mouse models in which β subunits of voltage-gated sodium channels are ablated or mutated exhibit a predisposition to seizures [48–52]. Notably, BACE1 levels are increased in the brains of patients with AD and hAPP mouse models of AD [48,53–60], and the magnitude of the increase is correlated with increased β2 subunit cleavage in the brains of patients with AD [48]. These studies suggest that BACE1-mediated cleavage of the β2 subunit may contribute to AD-related increase in principal cell activity, although this has yet to be determined.
Seizures in patients with Alzheimer's disease (AD) have been examined by many investigators over the last several decades, and there are diverse opinions about their potential relevance to AD pathophysiology. Some studies suggest that seizures appear to be a fairly uncommon co-morbidity, whereas other studies report a higher incidence of seizures in patients with AD. It was previously thought that seizures play a minor role in AD pathophysiology because of their low frequency, and also because they may only be noticed during late stages of AD, suggesting that seizures are likely to be a consequence of neurodegeneration rather than a contributing factor. However, clinical reports indicate that seizures can occur early in the emergence of AD symptoms, particularly in familial AD. In this case, seizures may be an integral part of the emerging pathophysiology. This view has been supported by evidence of recurrent spontaneous seizures in transgenic mouse models of AD in which familial AD is simulated. Additional data from transgenic animals suggest that there may be a much closer relationship between seizures and AD than previously considered. There is also evidence that seizures facilitate production of amyloid β (Aβ) and can cause impairments in cognition and behavior in both animals and humans. However, whether seizures play a role in the early stages of AD pathogenesis is still debated. Therefore, it is timely to review the similarities and differences between AD and epilepsy, as well as data suggesting that seizures may contribute to cognitive and behavioral dysfunction in AD. Here we focus on AD and temporal lobe epilepsy (TLE), a particular type of epilepsy that involves the temporal lobe, a region that influences behavior and is critical to memory. We also consider potential neurobiological mechanisms that support the view that the causes of seizures in TLE may be related to the causes of cognitive dysfunction in AD. We suggest that similar underlying mechanisms may exist for at least some of the aspects of AD that are also found in TLE.
This article is part of a Special Issue entitled “The Future of Translational Epilepsy Research”.
The miR-124 regulates the expression of BACE1/β-secretase correlated with cell death in Alzheimer's disease
2012, Toxicology Letters
Citation Excerpt :
The expression of miR-124 is enriched in neurons but not astrocytes, and its expression level increased over time in the developing nerve system (Krichevsky et al., 2003; Miska et al., 2004; Makeyev et al., 2007; Smirnova et al., 2005;). Moreover, it has been reported that the expression of miR-124 is down-regulated in the brains of patients with AD while the expression of BACE1 is up-regulated in these patients (BigI et al., 2000; Holsinger et al., 2002; Lukiw, 2007; Sun et al., 2002; Smith et al., 2011; Yang et al., 2003). Hence, in order to address the role and target gene regulation network of miR-124 in cellular AD model induced by Aβ1-42 neurotoxicity, we tested in vitro miRNA gain and loss of function in cellular AD model, elucidated the expression alteration of one of its potential downstream targets, BACE 1, and the profiles of cell death and survival following treatments with mimics or inhibitor of miR-124.
The role of miR-124 on the expression of β-site APP cleaving enzyme 1 (BACE1), an important cleavager of amyloid precursor protein that plays a pivotal role in the β-amyloid production, was studied in this paper using cellular models for Alzheimer’ disease (AD) of cultured PC12 cell lines and primary cultured hippocampal neurons. The aim of the present study was to uncover novel potential miR-124 targets and shed light on its function in the cellular AD model. MiR-124 expression was steadily altered when its mimic and inhibitor were transfected in vitro. The results showed the expression of BACE1, one of the potential functional downstream targets of miR-124, was well correlated with cell death induced by Aβ neurotoxicity, and its expression level could be up- and down-regulated by suppression or over expression of miR-124 level respectively. These findings suggest that miR-124 may work as a basilic regulating factor to alleviate cell death in the process of AD by targeting BACE1, play an essential role in the control of BACE1 gene expression, and might be considered as a novel therapeutic target in treating AD.
Enhanced activity of hippocampal BACE1 in a mouse model of postmenopausal memory deficits
2008, Neuroscience Letters
Ovarian hormone decline after menopause may influence cognitive performance and increase the risk for Alzheimer's disease (AD) in women. We have recently demonstrated that a combination of ovariectomy and chronic stress (OVX/stress) causes hippocampus-associated cognitive dysfunction in mice. In this study, we examined whether OVX/stress could affect the levels of AD-related molecules in the mouse hippocampus. Female ICR mice were ovariectomized or sham-operated, and then randomly divided into a daily restraint stress (21 days, 6 h/day) or non-stress group. Although OVX or stress alone did not affect β-site amyloid precursor protein (APP)-cleaving enzyme-1 (BACE1) activity, OVX/stress increased activity in hippocampal CA1 and CA3 regions, compared with other groups. In contrast, OVX/stress did not affect γ-secretase activity, Aβ_1-40, and phosphorylated-tau levels in the hippocampus. These findings suggest that a stressful life after menopause can influence the levels of AD-related molecules and that BACE1 is the most sensitive molecule for such a situation.

View all citing articles on Scopus

¹: To whom correspondence should be addressed at Department of Anatomy & Neurobiology, University of Kentucky Medical Center, Room 310, Davis-Mills Building, 800 Rose Street, Lexington, KY 40536. Fax: (859) 257-3625. E-mail: [email protected].

View full text

Regular ArticleLocalization of β-Secretase Memapsin 2 in the Brain of Alzheimer's Patients and Normal Aged Controls

Abstract

J. Biol. Chem.

J. Biol. Chem.

Neurosci. Lett.

Neuron

J. Biol. Chem.

Am. J. Pathol.

J. Biol. Chem.

Mol. Cell. Neurosci.

Mol. Cell. Neurosci.

Am. J. Pathol.

Neuroscience

J. Biol. Chem.

Cell

Am. J. Pathol.

J. Biol. Chem.

FEBS Lett.

J. Biol. Chem.

Biochem. Biophys. Res. Commun.

Neuron

J. Neurosci. Methods

Prog. Neurobiol.

Exp. Neurol.

Neurobiol. Aging

J. Biol. Chem.

J. Neurol. Sci.

Exp. Gerontol.

Regular Article
Localization of β-Secretase Memapsin 2 in the Brain of Alzheimer's Patients and Normal Aged Controls